Please assess the completion status of the following clinical trial:

Trial Title: Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years of age or older, and of any ethnic or racial group.~2. Diagnosis of unresectable metastatic colorectal adenocarcinoma with liver-dominant bilobar disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria.~3. Disease progression or intolerance to at least two prior Food and Drug Administration-approved therapeutic regimens.~4. If extrahepatic disease is present, it must be asymptomatic.~5. If a primary tumor is in place, it must be asymptomatic.~6. Measurable target tumors using standard imaging techniques (RECIST v. 1.1 criteria).~7. Tumor replacement \< 50% of total liver volume.~8. Current Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 through screening to first treatment on study.~9. Completion of prior systemic therapy at least 14 days prior to enrollment.~10. Able to understand informed consent.~Exclusion Criteria:~1. At risk of hepatic or renal failure~   * Serum creatinine \> 1.5 mg/dl~  * Serum bilirubin \> 1.3 mg/ml~  * Albumin \< 2.0 g/dL~  * Aspartate and/or alanine aminotransferase level \> 5 times upper normal limit~  * Any history of hepatic encephalopathy~  * Cirrhosis or portal hypertension~  * Clinically evident ascites (trace ascites on imaging is acceptable)~2. Contraindications to angiography and selective visceral catheterization~   * Any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)~  * Severe allergy or intolerance to contrast agents, narcotics, or sedatives that cannot be managed medically~3. Symptomatic lung disease~4. Prior therapy with Tas-102.~5. Contraindications to Tas-102~   * Absolute neutrophil count \< 1,500/μl~  * Platelet count \< 75,000/μl~  * Allergy or intolerance to Tas-102~6. Unresolved toxicity of greater than or equal to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 due to prior therapies.~7. Evidence of potential delivery of~   * Greater than 30 Gy absorbed dose of radiation to the lungs during a single 90Y resin microsphere administration; or~  * Cumulative delivery of radiation to the lungs \> 50 Gy over multiple treatments.~8. Evidence of any detectable Tc-99m macro aggregated albumin flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow.~9. Previous radiation therapy to the lungs and/or to the upper abdomen~10. Any prior arterial liver-directed therapy, including chemoembolization, bland embolization, and 90Y radioembolization~11. Any intervention for, or compromise of the ampulla of Vater~12. Active uncontrolled infection. Presence of latent or medication-controlled HIV and/or viral hepatitis is allowed.~13. Significant extrahepatic disease~    * Symptomatic extrahepatic disease (including primary tumor, if unresected).~   * Greater than 10 pulmonary nodules (each \< 20 mm in diameter) or combined diameter of all pulmonary nodules \> 15 cm.~   * Peritoneal carcinomatosis~14. Life expectancy less than 3 months~15. Pregnant or lactating female~16. In the investigator's judgment, any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of radioembolization or Tas-102.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tas-102 and radioembolization (Type: EXPERIMENTAL): Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete